"This study shows that newer biologic medications, while immunomodulatory, may be associated with lower serious infection rates than other oral and biologic medications for older people with psoriatic ...

While this result affirms Bimzelx’s efficacy in PsA, analysts do not believe this readout will have a notable impact on the ...

Dual therapy with a GLP-1 receptor agonist plus ixekizumab demonstrates long-term benefits in psoriatic disease activity, ...

Biologics targeting IL-12, IL-23, or IL-17 are linked to lower infection risk in older adults with psoriatic disease compared to other systemic treatments. The study utilized Ontario's health ...

Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults with psoriatic disease. Older systemic medications, including methotrexate, ...

Sun Pharma Announces US FDA Acceptance Of Supplemental Biologics License (Sbla) Application For ILUMYA® (Tildrakizumab-Asmn) For The Treatment Of Adults With Active Psoriatic Arthritis. If the sBLA is ...

The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.

In phase 3 clinical trials, tildrakizumab treatment was associated with significantly higher ACR20 response rates at week 24 compared with placebo.

UCB said it’s the first time an approved biologic demonstrated superiority over an IL-23 blocker in psoriatic arthritis. Yet analysts aren’t sure how commercially impactful the results will be.

Sun Pharmaceutical Industries Limited. Sun Pharma announces US FDA acceptance of supplemental Biologics License Application for ILUMYA (tildrakizumab-asmn) for the treatment of adults with active ...

Patients with psoriatic arthritis (PsA) who had a family history of psoriatic disease were diagnosed with psoriasis and PsA earlier and showed more entheseal involvement than those without such family ...